AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 292: R143-R149, 2007. First published August 3, 2006; doi:10.1152/ajpregu.00926.2005
0363-6119/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/1/R143    most recent
00926.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bradford, C. D.
Right arrow Articles by Gerrard, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bradford, C. D.
Right arrow Articles by Gerrard, D. F.

CALL FOR PAPERS
Physiology and Pharmacology of Temperature Regulation

Exercise can be pyrogenic in humans

Carl D. Bradford,1 James D. Cotter,1 Megan S. Thorburn,1 Robert J. Walker,2 and David F. Gerrard2

1School of Physical Education and 2Dunedin School of Medicine, University of Otago, New Zealand

Submitted 31 December 2005 ; accepted in final form 24 July 2006

Exercise increases mean body temperature (Tbody) and cytokine concentrations in plasma. Cytokines facilitate PG production via cyclooxygenase (COX) enzymes, and PGE2 can mediate fever. Therefore, we used a COX-2 inhibitor to test the hypothesis that PG-mediated pyrogenicity may contribute to the raised Tbody in exercising humans. In a double-blind, cross-over design, 10 males [age: 23 yr (SD 5), VO2 max: 53 ml·kg–1·min–1 (SD 5)] consumed rofecoxib (50 mg/day; NSAID) or placebo (PLAC) for 6 days, 2 wk apart. Exercising thermoregulation was measured on day 6 during 45-min running (~75% VO2 max) followed by 45-min cycling and 60-min seated recovery (28°C, 50% relative humidity). Plasma cytokine (TNF-{alpha}, IL-10) concentrations were measured at rest and 30-min recovery. Tbody was similar at rest in PLAC (35.59°C) and NSAID (35.53°C) and increased similarly during running, but became 0.33°C (SD 0.26) lower in NSAID during cycling (37.39°C vs. 37.07°C; P = 0.03), and remained lower throughout recovery. Sweating was initiated at Tbody of ~35.6°C in both conditions but ceased at higher Tbody in PLAC than NSAID during recovery [36.66°C (SD 0.36) vs. 36.39°C (SD 0.27); P = 0.03]. Cardiac frequency averaged 6·min–1 higher in PLAC (P < 0.01), whereas exercising metabolic rate was similar (505 vs. 507 W·m–2; P = 0.56). A modest increase in both cytokines across exercise was similar between conditions. COX-2 specific NSAID lowered exercising heat and cardiovascular strain and the sweating (offset) threshold, independently of heat production, indicating that PGE-mediated inflammatory processes may contribute to exercising heat strain during endurance exercise in humans.

body temperature regulation; sweating; inflammation; fever; cyclooxygenase inhibition



Address for reprint requests and other correspondence: J. D. Cotter, School of Physical Education, Univ. of Otago, P.O. Box 56, Dunedin, New Zealand (e-mail: jcotter{at}otago.ac.nz)




This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. A. Romanovsky
Thermoregulation: some concepts have changed. Functional architecture of the thermoregulatory system
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R37 - R46.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.